Levormeloxifene

Levormeloxifene
ファイル:Levormeloxifene.svg
Systematic (IUPAC) name
	1-(2-[4-[(3R,4R)-7-Methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy]ethyl)pyrrolidine
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	78994-23-7
ATC code	?
PubChem	CID 35805
ChemSpider	32935
UNII	9512UKZ352
ChEMBL	CHEMBL301327
Synonyms	Levomeloxifene; 6720-CDRI; NNC-460020
Chemical data
Formula	C30H35NO3
	InChI InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1 ; Key:XZEUAXYWNKYKPL-WDYNHAJCSA-N ;
(what is this?) (verify);

Levormeloxifene (INNTooltip International Nonproprietary Name; developmental code names 6720-CDRI, NNC-460020) is a selective estrogen receptor modulator (SERM) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed.^[1] The development was stopped because of a high incidence of gynecological side effects during clinical trials.^[2] Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.

References